Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)

NCT04652700 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

494

Enrollment

INDUSTRY

Sponsor class

Stopped Voluntarily terminated due to benefit/risk assessment.

Conditions

HIV Preexposure Prophylaxis

Interventions

DRUG: ISL
DRUG: FTC/TDF
DRUG: FTC/TAF
DRUG: Placebo to ISL
DRUG: Placebo to FTC/TDF
DRUG: Placebo to FTC/TAF

Sponsor

Merck Sharp & Dohme LLC